Schedule an appointment with us today
found that the protective effect of dulaglutide on learning and memory impairment might be the result of reducing the hyperphosphorylation of tau and neurolament proteins in a PI3K/AKT/GSK3bsignaling pathway-dependent manner (48)
Victoza Dosing Schedule (Type 2 Diabetes): For diabetes management, the dose starts at 0.6 mg daily and can be adjusted to 1.2 mg or 1.8 mg depending on the patients needs
GLP-1 Drugs on the Rise The Food and Drug Administration (FDA) has approved a new class of GLP-1 drugs, such as Wegovy, for treating obesity specifically, regardless of a patients history with or without type 2 diabetes
As researchers explore new therapeutic approaches, GLP-1 receptor agonistsmedications originally developed for type 2 diabetes and obesityhave emerged as a potential off-label treatment
The cardiovascular protection offered by GLP-1 receptor agonists stems from several complementary mechanisms: Anti-inflammatory effects through suppression of CRP, TNF-, and other inflammatory markers Substantial weight reduction, particularly with higher doses of newer agents Blood pressure modulation via direct vascular effects and enhanced natriuresis Improved endothelial function and lipid profiles Renal protective effects, including reduced albuminuria and slowed eGFR decline Though initially established in type 2 diabetes populations, recent evidence from the SELECT trial confirms these benefits extend to non-diabetic patients with obesity and established cardiovascular disease
/assets/images/provider/photos/2775905.jpeg)
